Skip to main content
. Author manuscript; available in PMC: 2015 Nov 1.
Published in final edited form as: Cancer Immunol Res. 2014 Aug 4;2(11):1090–1102. doi: 10.1158/2326-6066.CIR-14-0076

Figure 2.

Figure 2

Sunitinib plus rMVA-CEA-TRICOM vaccine decreased tumor burden and increased intratumoral infiltration of T lymphocytes in the MC38-CEA colon carcinoma model. A, volumes of 21-day-old MC38-CEA tumors from 52–58 CEA-Tg mice/group from 6 independent experiments. Circles: individual measurements; bars: mean±SEM. B, IHC of tumor sections harvested 21 days after tumor transplant from 3 mice/group analyzed for the T-cell marker CD3 (red-AF594) and the nuclear stain DAPI (blue). White arrows: CD3+ T lymphocytes. Scale bars: 25 µm. C, number of intratumoral CD3 T lymphocytes/mm2. D, percentage of CapM8 CEA-specific tumor-infiltrating CD8 T lymphocytes, calculated by flow-cytometry. The number of HIV-GAG+ lymphocytes was subtracted from the total of CapM8 CEA-tetramer+ events. Bars: mean ± SEM. Statistically significant difference based on ANOVA: *P<0.05; **P<0.01; *** P<0.001; ****P<0.0001.

HHS Vulnerability Disclosure